Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $66 | $28 | $265 | $731 |
| - Cash | $137 | $38 | $142 | $193 |
| + Debt | $12 | $12 | $13 | $12 |
| Enterprise Value | -$58 | $2 | $136 | $550 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -98.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$83 | -$53 | -$61 | -$48 |
| % Margin | – | – | -1,011,633.3% | -10,546.3% |
| Net Income | -$75 | -$58 | -$61 | -$33 |
| % Margin | – | – | -1,011,533.3% | -7,378.5% |
| EPS Diluted | -3.96 | -5.07 | -5.5 | -3.2 |
| % Growth | 21.9% | 7.8% | -71.9% | – |
| Operating Cash Flow | -$71 | -$46 | -$48 | -$25 |
| Capital Expenditures | -$1 | -$1 | -$3 | -$2 |
| Free Cash Flow | -$71 | -$47 | -$51 | -$27 |